ZBH — ZIMMER BIOMET HOLDINGS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ZBH?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their ZBH position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.
- +2 tracked investors added or increased positions last quarter (Steve Cohen, Ray Dalio)
- +5 tracked investors reported holding ZBH at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About ZIMMER BIOMET HOLDINGS INC (ZBH)
ZIMMER BIOMET HOLDINGS INC (ZBH) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $316M. Across recent filings, tracked investors recorded 2 new positions, 7 increased, 4 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ZBH
How many top investors track ZBH
A small number of top investors own this.
ZBH Ownership Composition
How ZIMMER BIOMET HOLDINGS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant97.7%
- Macro2.3%
Tracked investors currently reporting ZBH
- Ken GriffinJun 30, 2026Citadel AdvisorsShares3.7MValue$316.1M% Portfolio0.04%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares222.1KValue$19.1M% Portfolio0.01%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares893.8KValue$76.9M% Portfolio0.08%
- Ray DalioJun 30, 2026Bridgewater AssociatesShares36.2KValue$3.1M% Portfolio0.01%
- Paul Tudor JonesJun 30, 2026Tudor Investment CorpShares77.8KValue$6.7M% Portfolio0.01%
Recent activity
- Increased$38.8M(8.00%)Feb 14, 2024
- Increased$46.8M(11.20%)May 14, 2024
- Reduced$38.2M(-0.94%)Aug 14, 2024
- Reduced$19.5M(-48.62%)Nov 13, 2024
- Increased$21.2M(11.00%)Feb 13, 2025
- Reduced$964.4K(-95.75%)May 14, 2025
- Reduced$598.4K(-23.00%)Aug 13, 2025
- Increased$1.2M(91.27%)Nov 13, 2025
- Increased$2.8M(148.85%)Feb 13, 2026
- Increased$3.1M(8.85%)May 15, 2026
- Increased$3.1M(6.35%)Aug 14, 2026
- New$76.9MAug 14, 2026
- New$33.2MNov 13, 2023
Frequently asked questions
- How many institutional investors hold ZBH?
- 5 tracked institutional investors disclosed a position in ZBH (ZIMMER BIOMET HOLDINGS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ZBH?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ZBH, valued at $316M.
- Did institutional ownership of ZBH increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 7 increased, 4 reduced, and 0 fully exited ZBH.
- Where does this ZBH ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.